{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:56:27Z","timestamp":1777935387127,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T00:00:00Z","timestamp":1528070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00393-018-0484-8","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T09:53:32Z","timestamp":1528106012000},"page":"677-684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Versorgungssituation der\u00a0Riesenzellarteriitis in\u00a0Rheinland\u2011Pfalz","Current patient care of giant cell arteritis in Rhineland-Palatinate"],"prefix":"10.1007","volume":"78","author":[{"given":"Christian","family":"von Kiel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Triantafyllias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,4]]},"reference":[{"key":"484_CR1","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1136\/ard.2010.149351","volume":"70","author":"C Beyer","year":"2011","unstructured":"Beyer C, Axmann R, Sahinbegovic E et al (2011) Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 70:1874\u20131875","journal-title":"Ann Rheum Dis"},{"key":"484_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.semarthrit.2012.12.023","volume":"43","author":"H Boysson De","year":"2013","unstructured":"De Boysson H, Boutemy J, Creveuil C et al (2013) Is there a\u00a0place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum 43:105\u2013112","journal-title":"Semin Arthritis Rheum"},{"key":"484_CR3","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","volume":"77","author":"C Dejaco","year":"2018","unstructured":"Dejaco C, Ramiro S, Duftner C et\u00a0al (2018) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 77:636\u2013643","journal-title":"Ann Rheum Dis"},{"key":"484_CR4","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/1529-0131(199811)41:11<1960::AID-ART10>3.0.CO;2-X","volume":"41","author":"P Duhaut","year":"1998","unstructured":"Duhaut P, Pinede L, Demolombe-Rague S et al (1998) Giant cell arteritis and cardiovascular risk factors: a\u00a0multicenter, prospective case-control study. Groupe de Recherche sur l\u2019Arterite a\u00a0Cellules Geantes. Arthritis Rheum 41:1960\u20131965","journal-title":"Arthritis Rheum"},{"key":"484_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/imj.12293","volume":"44","author":"E Dunstan","year":"2014","unstructured":"Dunstan E, Lester SL, Rischmueller M et al (2014) Epidemiology of biopsy-proven giant cell arteritis in South Australia. Intern Med\u00a0J 44:32\u201339","journal-title":"Intern Med J"},{"key":"484_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/01.md.0000180042.42156.d1","volume":"84","author":"MA Gonzalez-Gay","year":"2005","unstructured":"Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ et al (2005) Giant cell arteritis: disease patterns of clinical presentation in a\u00a0series of 240 patients. Medicine (Baltimore) 84:269\u2013276","journal-title":"Medicine (Baltimore)"},{"key":"484_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/md.0b013e31803d1764","volume":"86","author":"MA Gonzalez-Gay","year":"2007","unstructured":"Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ et al (2007) Giant cell arteritis in northwestern Spain: a\u00a025-year epidemiologic study. Medicine (Baltimore) 86:61\u201368","journal-title":"Medicine (Baltimore)"},{"key":"484_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11926-014-0480-1","volume":"17","author":"MA Gonzalez-Gay","year":"2015","unstructured":"Gonzalez-Gay MA, Pina T (2015) Giant cell arteritis and polymyalgia rheumatica: an update. Curr Rheumatol Rep 17:6","journal-title":"Curr Rheumatol Rep"},{"key":"484_CR9","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/art.24459","volume":"61","author":"MA Gonzalez-Gay","year":"2009","unstructured":"Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ et al (2009) Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 61:1454\u20131461","journal-title":"Arthritis Rheum"},{"key":"484_CR10","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/rheumatology\/ket440","volume":"53","author":"K Herlyn","year":"2014","unstructured":"Herlyn K, Buckert F, Gross WL et al (2014) Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany. Rheumatology (Oxford) 53:882\u2013889","journal-title":"Rheumatology (Oxford)"},{"key":"484_CR11","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/art.10262","volume":"46","author":"GS Hoffman","year":"2002","unstructured":"Hoffman GS, Cid MC, Hellmann DB et al (2002) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46:1309\u20131318","journal-title":"Arthritis Rheum"},{"key":"484_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","volume":"146","author":"GS Hoffman","year":"2007","unstructured":"Hoffman GS, Cid MC, Rendt-Zagar KE et al (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a\u00a0randomized trial. Ann Intern Med 146:621\u2013630","journal-title":"Ann Intern Med"},{"key":"484_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.7326\/0003-4819-82-5-613","volume":"82","author":"GG Hunder","year":"1975","unstructured":"Hunder GG, Sheps SG, Allen GL et al (1975) Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a\u00a0prospective study. Ann Intern Med 82:613\u2013618","journal-title":"Ann Intern Med"},{"key":"484_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ejim.2008.07.030","volume":"20","author":"M Khalifa","year":"2009","unstructured":"Khalifa M, Karmani M, Jaafoura NG et\u00a0al (2009) Epidemiological and clinical features of giant cell arteritis in Tunisia. Eur J Intern Med 20:208\u2013212","journal-title":"Eur J Intern Med"},{"key":"484_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/art.11195","volume":"49","author":"S Kobayashi","year":"2003","unstructured":"Kobayashi S, Yano T, Matsumoto Y et al (2003) Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a\u00a0nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 49:594\u2013598","journal-title":"Arthritis Rheum"},{"key":"484_CR16","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1002\/art.22141","volume":"54","author":"MS Lee","year":"2006","unstructured":"Lee MS, Smith SD, Galor A et\u00a0al (2006) Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54:3306\u20133309","journal-title":"Arthritis Rheum"},{"key":"484_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0002-9343(01)00770-7","volume":"111","author":"E Liozon","year":"2001","unstructured":"Liozon E, Herrmann F, Ly K et\u00a0al (2001) Risk factors for visual loss in giant cell (temporal) arteritis: a\u00a0prospective study of 174 patients. Am J Med 111:211\u2013217","journal-title":"Am J Med"},{"key":"484_CR18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.semarthrit.2014.12.005","volume":"44","author":"J Loricera","year":"2015","unstructured":"Loricera J, Blanco R, Hernandez JL et al (2015) Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients. Semin Arthritis Rheum 44:717\u2013723","journal-title":"Semin Arthritis Rheum"},{"key":"484_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/ard.2007.082115","volume":"67","author":"VM Martinez-Taboada","year":"2008","unstructured":"Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L et al (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67:625\u2013630","journal-title":"Ann Rheum Dis"},{"key":"484_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/ard.2008.088351","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC et\u00a0al (2009) EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68:318\u2013323","journal-title":"Ann Rheum Dis"},{"key":"484_CR21","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/rheumatology\/35.11.1161","volume":"35","author":"G Myklebust","year":"1996","unstructured":"Myklebust G, Gran JT (1996) A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 35:1161\u20131168","journal-title":"Br J Rheumatol"},{"key":"484_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/rheumatology\/31.2.103","volume":"31","author":"AB Myles","year":"1992","unstructured":"Myles AB, Perera T, Ridley MG (1992) Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol 31:103\u2013105","journal-title":"Br J Rheumatol"},{"key":"484_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/01.md.0000119761.27564.c9","volume":"83","author":"G Nesher","year":"2004","unstructured":"Nesher G, Berkun Y, Mates M et\u00a0al (2004) Risk factors for cranial ischemic complications in giant cell arteritis. Medicine (Baltimore) 83:114\u2013122","journal-title":"Medicine (Baltimore)"},{"key":"484_CR24","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/art.20171","volume":"50","author":"G Nesher","year":"2004","unstructured":"Nesher G, Berkun Y, Mates M et al (2004) Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50:1332\u20131337","journal-title":"Arthritis Rheum"},{"key":"484_CR25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/acr.22429","volume":"67","author":"H Petri","year":"2015","unstructured":"Petri H, Nevitt A, Sarsour K et al (2015) Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities. Arthritis Care Res (Hoboken) 67:390\u2013395","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"484_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/art.21075","volume":"53","author":"C Salvarani","year":"2005","unstructured":"Salvarani C, Cimino L, Macchioni P et al (2005) Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 53:293\u2013297","journal-title":"Arthritis Rheum"},{"key":"484_CR27","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.3899\/jrheum.110496","volume":"38","author":"S Sciascia","year":"2011","unstructured":"Sciascia S, Rossi D, Roccatello D (2011) Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J\u00a0Rheumatol 38:2080\u20132081","journal-title":"J Rheumatol"},{"key":"484_CR28","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","volume":"73","author":"R Seror","year":"2014","unstructured":"Seror R, Baron G, Hachulla E et al (2014) Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a\u00a0multicentre randomised controlled trial. Ann Rheum Dis 73:2074\u20132081","journal-title":"Ann Rheum Dis"},{"key":"484_CR29","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1002\/acr.21750","volume":"64","author":"S Unizony","year":"2012","unstructured":"Unizony S, Arias-Urdaneta L, Miloslavsky E et al (2012) Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 64:1720\u20131729","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"484_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12891-016-1127-3","volume":"17","author":"M Yates","year":"2016","unstructured":"Yates M, Graham K, Watts RA et\u00a0al (2016) The prevalence of giant cell arteritis and polymyalgia rheumatica in a\u00a0UK primary care population. BMC Musculoskelet Disord 17:285","journal-title":"BMC Musculoskelet. Disord."}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0484-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0484-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0484-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T17:52:45Z","timestamp":1588009965000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0484-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,4]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0484-8","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,4]]},"assertion":[{"value":"4 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0von Kiel, M.\u00a0Dreher, K.\u00a0Triantafyllias, P.\u00a0Heinz und A.\u00a0Schwarting geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}